Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osivelotor - Global Blood Therapeutics/Pfizer

Next Previous
Drug Profile

Osivelotor - Global Blood Therapeutics/Pfizer

Alternative Names: GBT-021601; GBT-601; PF-07940367

Latest Information Update: 31 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Global Blood Therapeutics; Pfizer
  • Class Alcohols; Antianaemics; Benzaldehydes; Ketones; Methyl ethers; Morpholines; Phenols; Phenyl ethers; Pyridines; Small molecules; Urologics
  • Mechanism of Action Sickle haemoglobin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase I Renal failure

Most Recent Events

  • 20 Mar 2026 Phase-II/III clinical trials in Sickle cell anaemia (In adolescents, In adults, In the elderly) in India, United Kingdom (PO) (NCT05431088)
  • 28 Feb 2026 No recent reports of development identified for phase-I development in Sickle-cell-anaemia(In volunteers) in Netherlands (PO)
  • 06 Dec 2025 Efficacy and adverse events data from a phase II/III OLE trial in Sickle cell anaemia presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top